Drug:
Reaction: DERMATITIS ATOPIC
20250101 - 20251231
No. 201 - 300
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 201 | 25121433 |
US |
53 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 202 | 25121579 |
US |
2 | |
Dermatitis atopic, Pruritus, Erythema, |
||||
DUPILUMAB, |
||||
| 203 | 25121698 |
US |
44 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 204 | 25121764 |
US |
39 | 1 |
Dermatitis atopic, Dry skin, Pruritus, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 205 | 25121882 |
US |
19 | 1 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 206 | 25121901 |
US |
40 | 1 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 207 | 25122280 |
US |
36 | 2 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 208 | 25122320 |
US |
27 | 1 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 209 | 25122332 |
US |
39 | 1 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, TRALOKINUMAB-LDRM, TRALOKINUMAB-LDRM, TRALOKINUMAB-LDRM, TRALOKINUMAB-LDRM, TRALOKINUMAB-LDRM, |
||||
| 210 | 25123224 |
US |
38 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 211 | 25123235 |
US |
1 | |
Rash macular, Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 212 | 25123237 |
US |
30 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 213 | 25123248 |
US |
41 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 214 | 25123252 |
US |
1 | |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, SIMVASTATIN, |
||||
| 215 | 25123253 |
US |
1 | |
Dermatitis atopic, Drug effect less than expected, |
||||
DUPILUMAB, |
||||
| 216 | 25123258 |
US |
44 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 217 | 25123261 |
US |
51 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, CERTOLIZUMAB PEGOL, |
||||
| 218 | 25123262 |
US |
40 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 219 | 25123286 |
US |
6 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 220 | 25123304 |
US |
87 | 2 |
Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 221 | 25123344 |
US |
12 | 2 |
Dermatitis, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 222 | 25124035 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 223 | 25124037 |
US |
11 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 224 | 25124050 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 225 | 25124052 |
US |
17 | 2 |
Sleep disorder, Oligomenorrhoea, Dysmenorrhoea, Dry eye, Dermatitis atopic, Skin exfoliation, Skin fissures, Dry skin, Pruritus, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 226 | 25124061 |
US |
70 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 227 | 25124078 |
US |
43 | 2 |
Stress, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 228 | 25124082 |
US |
50 | 1 |
Dermatitis atopic, Rash papular, |
||||
DUPILUMAB, |
||||
| 229 | 25124160 |
US |
50 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 230 | 25124305 |
US |
35 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 231 | 25124314 |
US |
19 | 2 |
Dermatitis atopic, Treatment failure, |
||||
CRISABOROLE, |
||||
| 232 | 25124734 |
US |
39 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 233 | 25124896 |
US |
63 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 234 | 25125135 |
US |
12 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 235 | 25125159 |
US |
42 | 1 |
Dermatitis atopic, Asthma, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 236 | 25125165 |
US |
20 | 1 |
Discomfort, Sleep disorder due to a general medical condition, Pain of skin, Rash, Dermatitis atopic, |
||||
DUPILUMAB, CHLORHEXIDINE GLUCONATE, ANTISEPTIC SKIN CLEANSER, EPINEPHRINE, ADRENALINUM, |
||||
| 237 | 25125456 |
US |
57 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 238 | 25125565 |
US |
1 | |
Dementia Alzheimer^s type, Dry skin, Asthma, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 239 | 25126037 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 240 | 25126058 |
US |
19 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 241 | 25126167 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 242 | 25126225 |
US |
2 | |
Dermatitis atopic, Rash erythematous, |
||||
DUPILUMAB, |
||||
| 243 | 25115635 |
US |
52 | 2 |
Stress, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 244 | 25115648 |
US |
2 | |
Dermatitis, Asthma, Dermatitis atopic, Arthralgia, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 245 | 25116066 |
US |
63 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 246 | 25116218 |
US |
44 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 247 | 25116238 |
US |
26 | 2 |
Rash, Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 248 | 25116241 |
US |
61 | 1 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 249 | 25116313 |
US |
24 | 1 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 250 | 25116323 |
US |
46 | 2 |
Gastric bypass, Dermatitis atopic, |
||||
UPADACITINIB, |
||||
| 251 | 25116980 |
US |
33 | 2 |
Abortion spontaneous, Dermatitis atopic, Maternal exposure during pregnancy, |
||||
DUPILUMAB, |
||||
| 252 | 25117450 |
US |
54 | 2 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 253 | 25118454 |
US |
21 | 2 |
Dermatitis atopic, Therapeutic product effect incomplete, |
||||
CRISABOROLE, |
||||
| 254 | 25118572 |
US |
2 | |
Drug hypersensitivity, Dermatitis atopic, Inappropriate schedule of product administration, |
||||
COLCHICINE, DUPILUMAB, |
||||
| 255 | 25118720 |
US |
||
Dermatitis atopic, Malignant neoplasm progression, Product use in unapproved indication, |
||||
OSIMERTINIB, DUPILUMAB, DUPILUMAB, LIOTHYRONINE SODIUM, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, APIXABAN, |
||||
| 256 | 25118750 |
US |
||
Therapy non-responder, Dermatitis atopic, |
||||
LEBRIKIZUMAB-LBKZ, |
||||
| 257 | 25118885 |
US |
53 | 2 |
Dermatitis atopic, Urticaria, Pruritus, Rash macular, Product storage error, |
||||
DUPILUMAB, |
||||
| 258 | 25118957 |
US |
27 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, Intentional product misuse, |
||||
DUPILUMAB, |
||||
| 259 | 25118962 |
US |
42 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 260 | 25118965 |
US |
11 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 261 | 25118984 |
US |
18 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 262 | 25119011 |
US |
36 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 263 | 25119022 |
US |
58 | 2 |
Pain, Pain in extremity, Dermatitis atopic, Arthralgia, |
||||
DUPILUMAB, |
||||
| 264 | 25119024 |
US |
33 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 265 | 25119036 |
US |
2 | |
Weight increased, Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 266 | 25119058 |
US |
62 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 267 | 25119064 |
US |
20 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 268 | 25119093 |
US |
51 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 269 | 25119094 |
US |
17 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 270 | 25119096 |
US |
25 | 1 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 271 | 25119097 |
US |
1 | |
Sleep disorder due to a general medical condition, Dermatitis atopic, Rash, Skin discomfort, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 272 | 25119110 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 273 | 25119114 |
US |
69 | 1 |
Dermatitis acneiform, Dermatitis atopic, Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 274 | 25119133 |
US |
38 | 2 |
Dermatitis atopic, Rash erythematous, |
||||
DUPILUMAB, |
||||
| 275 | 25119143 |
US |
29 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 276 | 25119160 |
US |
73 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 277 | 25119194 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 278 | 25119196 |
US |
29 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 279 | 25119226 |
US |
50 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 280 | 25119254 |
US |
23 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 281 | 25119324 |
US |
4 | 2 |
Vision blurred, Condition aggravated, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 282 | 25119339 |
US |
9 | 2 |
Exposure to household chemicals, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 283 | 25119500 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 284 | 25119667 |
US |
43 | 1 |
Dermatitis atopic, Psoriasis, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 285 | 25119852 |
US |
43 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 286 | 25120166 |
US |
13 | 1 |
Dermatitis atopic, Erythema, Rash macular, Product dose omission issue, |
||||
DUPILUMAB, SOMATROPIN, |
||||
| 287 | 25120637 |
CA |
||
Colitis ulcerative, Chest discomfort, Hypertension, Muscle spasms, Dermatitis atopic, Pruritus, |
||||
BENRALIZUMAB, PREDNISONE, FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, ALBUTEROL SULFATE, DUPILUMAB, |
||||
| 288 | 25109771 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 289 | 25109948 |
US |
5 | 1 |
Sensitivity to weather change, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 290 | 25109951 |
US |
28 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 291 | 25110012 |
US |
1 | |
Dermatitis atopic, Pruritus, Inflammation, |
||||
DUPILUMAB, |
||||
| 292 | 25110346 |
US |
31 | 2 |
Dermatitis atopic, Pain, |
||||
TRALOKINUMAB-LDRM, |
||||
| 293 | 25110975 |
US |
50 | 1 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 294 | 25110999 |
US |
52 | 2 |
Rash macular, Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 295 | 25111821 |
US |
58 | 2 |
Dermatitis atopic, Rosacea, Condition aggravated, |
||||
ABROCITINIB, |
||||
| 296 | 25114219 |
US |
2 | |
Dermatitis atopic, Rash macular, Condition aggravated, Pruritus, |
||||
DUPILUMAB, |
||||
| 297 | 25114240 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 298 | 25114260 |
US |
65 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 299 | 25114281 |
US |
17 | 2 |
Dermatitis atopic, Pruritus, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 300 | 25114297 |
US |
57 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28